

ACC Latin America Conference 2017



MEXICO CITY JUNE 22 – 24, 2017

Common Dilemmas in ACS and SIHD

"Cardiogenic Shock in STEMI"

Moderator: Marco A. Martínez Ríos

GLOBAL EXPERTS, LOCAL LEARNING



CARDIOGENIC SHOCK IN STEMI

Case Presenter: Armando García-Castillo MD FACC Interventional Cardiology Governor ACC Chapter MEXICO

DISCLOSURE



Categories of potential conflict of interest

Sponsoring of transport and/or hotel accommodations in Congresses

Sponsored in clinical trials and/or in basic research funded by pharmaceutical companies

Speaker in meetings sponsored by pharmaceutical companies

Participate in normative committees of scientific trials sponsored by pharmaceutical companies

Receive institutional support from pharmaceutical companies

Writing of educative materials sponsored by pharmaceutical companies

Hold stocks from pharmaceutical companies

Company

SANOFI, Pfizer AstraZeneca, MSD, Servier, Medtronico, Boston Sci, Abbot Vascular

SANOFI, AZ, Daichi, Esai, AMGEN

SANOFI, AZ, Pfizer, MSD, Abbot

SANOFI, , Daichi, Esai

BI, MSD, Pfizer, Sanofi

CLINICAL CASE




- * MLA male 65 years old
- Smoking suspended in 2003
- HTN dx in 2006
- PCI in 2003 with BMS to LAD & RC for UA
- PCI in 2007 with DES to LAD & RC secondary to progression disease
- Asymptomatic from 2007 to 2016 with several negative echostress tests
- On Jan 2017 during excercise activities developed chest pain and syncope
- Receive CPR in home and was transfered to Tertiary Hospital
- Arrive to ER with BP 80/40 HR 100x and short breath 8x
- Presented VF requiring AED with 200 joules and intubation
- Was transfered immediatly to cath lab

BASAL EKG



ACC Latin America Conference 2017






ACC Latin America Conference 2017

Coronary Angiogram


XΑ



PCI








MARIO ALBERTO LEAL ALANIS M 96248 19-January-1951 XA DOCTORS HOSPITAL AluraXper 5-January-2017 15:02:48

ΡСΙ







ACC Latin America Conference 2017

MARIO ALBERTO LEAL ALANIS Me 96248 19-January-1951 XA DOCTORS HOSPITAL AlluraXper 5-January-2017 15:02:48

Coronaria izda 15 ips

L: 128.75 W: 189.75

P C I









L: 128.75 W: 189.75

Clinical Evolution



- After succesfull PCI arrives to ICU with BP 105/70 $\,$ HR 90 and MV 14x $\acute{}$
- MV was retired 48 hours later
- Developed AKD with creatinine elevation until 6.2 mg and requeried haemodyalisis
- Renal function was recovered on 7th day and Majurkal catheter was removed
- Levels of BNP reached > 5000 pcg/dl
- Patient was discharged on 10th day of MI
- Predischarge TTE showed EF 40%


In Hospital & Diascharge Pharmacological Therapy



- Dopamine and Levosimendan inotropic agnets
- IV Nitroglicerin
- Bisoprolol 2.5 mg TID
- Ramipril 2.5 mg TID
- Rosuvastatin 40 mg QD
- Ticagrelor 90 mg BID
- Aspirin 100 mg QD
- Furosemide 40 mg QD


DISCHARGE EKG





DISCHARGE TTE







TEACHING POINTS

- Imperative developing Regional Networks of
 - **Reperfusion Therapy**
- To spread massively the App "Codigo Infarto"
- CS treated in the first hours get good results




CONTROVERSY POINTS

- IABP in CS : Routine pre PCI or Bailout?
- VAD (Impella): Convenient or Indispensable?
- ECMO: Routine for Refractary CS?
- PCI approach: Culprit lesion or Multivascular?



Percutaneous assist devices in cardiogenic shock.



Werdan K et al. Eur Heart J 2014;35:156-167


Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com








Trial Flow and Treatment









Thiele et al. Lancet 2013;382:1638-1645











ACC Latin America Conference 2017





ECLS Registry Report

International Summary January, 2016



Extracorporeal Life Support Organization 2800 Plymouth Road Building 300, Room 303 Ann Arbor, MI 48109

	over all outcomes				
	Total Patients	Survived ECLS		Survived to DC or Transfe	
Neonatal					
Respiratory	28,723	24,155	84%	21,274	74%
Cardiac	6,269	3,885	62%	2,599	41%
ECPR	1,254	806	64%	514	41%
Pediatric					
Respiratory	7,210	4,787	66%	4,155	58%
Cardiac	8,021	5,341	67%	4,067	51%
ECPR	2,788	1,532	55%	1,144	41%
Adult					
Respiratory	9,102	5,989	66%	5,254	58%
Cardiac	7,850	4,394	56%	3,233	41%
ECPR	2,379	948	40%	707	30%
Total	73,596	51,837	70%	42,947	58%

<u>Cardiac</u> - 7850 pts 56% survived ECLS 41% survived to DC ECPR 2379 → 30% survived to DC

<u>Respiratory</u> – 9102 pts 66% survived ECLS 58% survived to DC

